Etomoxir was in clinical development for the treatment of lung cancer and went through preclinical trials by Byk Gulden laboratories (now Altana Pharma AG) from 1981 to 1984.
Etomoxir has already been through phase II clinical development for the treatment of type 2 diabetes and heart failure. 
